期刊文献+

沙格列汀联合二甲双胍治疗2型糖尿病的疗效观察 被引量:4

Observation on Efficacy of Saxagliptin Combined with Metformin in Treatment of Type Ⅱ Diabetes Mellitus
下载PDF
导出
摘要 目的:探讨沙格列汀联合二甲双胍治疗2型糖尿病的疗效。方法:选取2017年6月至2018年6月广州中医药大学顺德医院收治的2型糖尿病患者200例,随机分为对照组和观察组,每组100例。对照组患者给予二甲双胍治疗,观察组患者给予沙格列汀联合二甲双胍治疗。观察两组患者的临床疗效、不良反应发生情况、血糖水平[空腹血糖(FPG)、餐后2 h血糖(2 hPG)及糖化血红蛋白(HbA_1c)]及体质量指数(BMI)。结果:观察组患者的总有效率为92.0%(92/100),明显高于对照组的72.0%(72/100),差异有统计学意义(P<0.05);观察组患者的不良反应发生率为4.0%(4/100),明显低于对照组的12.0%(12/100),差异有统计学意义(P<0.05);治疗后,观察组患者FPG、2 hPG、HbA_1c及BMI水平明显优于对照组,差异均有统计学意义(P<0.05)。结论:沙格列汀联合二甲双胍治疗2型糖尿病的疗效显著,较单用二甲双胍更具优势,可控制患者血糖及体质量,且不良反应少,安全性较高。 OBJECTIVE:To probe into the efficacy of saxagliptin combined with metformin in treatment of typeⅡdiabetes mellitus.METHODS:200 patients with typeⅡdiabetes mellitus admitted into Shunde Hospital of Guangzhou University of Chinese Medicine from Jun.2017 to Jun.2018 were selected and randomly divided into control group and observation group,with 100 cases in each.The control group was treated with metformin,while the observation group was given saxagliptin combined with metformin.The clinical efficacy,incidences of adverse drug reactions,blood glucose levels[fasting plasma glucose(FPG),2 h postprandial blood glucose(2 hPG)and glycosylated hemoglobin(HbA1c)]can body mass index(BMI)of two groups were observed.RESULTS:The total effective rate of observation group was 92.0%(92/100),which was significantly higher than that of the control group(72.0%,72/100),with statistically significant difference(P<0.05);the incidence of adverse drug reactions of observation group was 4.0%(4/100),which was significantly lower than that of the control group(12.0%,12/100),with statistically significant difference(P<0.05);after treatment,the FPG,2 hPG,HbA1c and BMI levels of observation group were significantly better than that of the control group,with statistically significant differences(P<0.05).CONCLUSIONS:The efficacy of saxagliptin combined with metformin in treatment of typeⅡdiabetes mellitus is remarkable and more significant than that of metformin alone,which can control patients'blood glucose and BMI,with few adverse drug reactions and high safety.
作者 谈凤联 林达秋 TAN Fenglian;LIN Daqiu(Dept.of Endocrinology,Shunde Hospital of Guangzhou University of Chinese Medicine,Guangdong Foshan 528300,China;Dept.of the Third Outpatient,Shunde Hospital of Guangzhou University of Chinese Medicine,Guangdong Foshan 528300,China)
出处 《中国医院用药评价与分析》 2019年第2期188-189,191,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 二甲双胍 2型糖尿病 沙格列汀 Metformin TypeⅡdiabete mellitus Salgletine
  • 相关文献

参考文献13

二级参考文献80

  • 1宋燕庆.二甲双胍联合沙格列汀与二甲双胍单药治疗2型糖尿病疗效比较[J].兵团医学,2013(4):18-19. 被引量:2
  • 2中华医学会糖尿病学分会.中国2型糖尿病防治指南/2010年版[M].北京:北京大学医学出版社,2011:5.
  • 3Barnett AH,Charbonnel B,Moses RG,et al.Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus[J].Curr Med Res Opin,2015;31(10):1919-31.
  • 4Scirica BM,Braunwald E,Raz I,et al.Heart failure,saxagliptin,and diabetes mellitus:observations from the SAVOR-TIMI 53 randomized tria[J].Circulation,2015;132(6):e120.
  • 5Matthaei S,Catrinoiu D,Celiński A,et al.Randomized,double-blind tria of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes[J].Diabetes Care,2015;38(11):2018-24.
  • 6DeF ronzo RA,Hissa MN,Garber AJ,et al.The efficacy and safety of saxagliptin when added to metformin therapy in patients with inad-equately controlled type 2 diabetes with metformin alone[J].Diabetes Care,2009;32(9):1649-55.
  • 7Jadzinsky M,Pfutzner A,Paz-Pacheco E,et al.Saxagliptin given in combination with metformin as initial therapy improves glycae-mic control in patients with type 2 diabetes compared with either monotherapy:A randomized controlled tria[lJ].Diabet Obes Metab,2009;11(6):611-22.
  • 8Yang W,Pan CY,Tou C,et al.Efficacy and safety saxagliptin added to metformin in Asian people with type 2 diabetes melitus:a randomized contrrolled tria[lJ].Diabet Res Clin Pract,2011;94(2):217-24.
  • 9Mosenzon O,Wei C,Davidson J,et al.Incidence of fractures in patients with type 2 diabetes in the SAVOR-TIMI 53 trial[J].Diabetes Care,2015;38(11):2142-50.
  • 10Pech V,Abusaada K,Alemany C.Dipeptidyl peptidase-4 inhibition may stimulate progression of carcinoid tumor[J].Case Rep Endocrinol,2015;2015(1):952019.

共引文献229

同被引文献35

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部